<DOC>
	<DOCNO>NCT00191126</DOCNO>
	<brief_summary>Preoperative chemotherapy consider play role early stage non small cell lung cancer ( NSCLC ) .The use preoperative Cisplatin/Gemcitabine chemotherapy proven feasible without excessive morbidity mortality Phase II setting . The aim present Phase III study determine whether 3 cycle preoperative chemotherapy Cisplatin/Gemcitabine improve progression free survival NSCLC patient versus surgery alone . Postoperative chemotherapy utilized Phase III trial .</brief_summary>
	<brief_title>Randomized Phase III Trial Surgery Alone Surgery Plus Preoperative Gemcitabine-Cisplatin Early Stages NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Main inclusion Criteria : Must pathologic documentation nonsmall cell lung cancer , IB , II , IIIA . ECOG Performance Status 0 1 Bidimensionally measurable disease evaluable disease Adequate organ function Main exclusion Criteria : Have great Grade 1 neuropathy motor/sensory Significant history cardiac disease Pleural effusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>